According to a statement issued by the city-based pharma firm, total revenues were up by 12.3 per cent to Rs 505.4 crore in the quarter against Rs 450 crore in the October-December period of last fiscal.
Laurus CEO Satyanarayana Chava said the results for the quarter were in line with the company's broader objectives.
V V Ravi Kumar, Executive Director and Chief Financial Officer, said, "As we continue to improve our financial performance we also focused on strengthening our balance sheet and prepaid Rs 2,263 million towards debt obligations from the IPO proceeds.
As on date, the company has filed two ANDAs (Abbreviated New Drug Applications) and in addition completed four product validations. The capacity expansion of 5 billion tablets is expected to complete by end-March, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
